Metionina

Volver al artículo.

Referencias para el artículo

  1. Muller F, Svardal AM, Aukrust P, et al. Elevated plasma concentration of reduced homocysteine in patients with Human Immunodeficiency Virus infection. Am J Clin Nutr 1996;63:242–6.
  2. Revillard JP, Vincent CM, Favier AE, et al. Lipid peroxidation in Human Immunodeficiency Virus infection. J Acquir Immune Defic Syndr 1992;5:637–8.
  3. Singer P, Katz DP, Dillon L, et al. Nutritional aspects of the Acquired Immunodeficiency Syndrome. Am J Gastroenterol 1992;87:265–73.
  4. Tan SV, Guiloff RJ. Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS. J Neurol Neurosurg Psychiatry 1998 65:23–8.
  5. Keating JN, Trimble KC, Mulcahy F, et al. Evidence of brain methyltransferase inhibition and early brain involvement in HIV-positive patients. Lancet 1991;337:935–9.
  6. Dorfman D, DiRocco A, Simpson D, et al. Oral methionine may improve neuropsychological function in patients with AIDS myelopathy: results of an open-label trial. AIDS 1997;11:1066–7.
  7. Smythies JR, Halsey JH. Treatment of Parkinson’s disease with l-methionine. South Med J 1984;77:1577.
  8. Charlton CG, Mack J. Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Support for an excess methylation hypothesis for parkinsonism. Mol Neurobiol 1994;9:149–61.
  9. Crowell BG Jr, Benson R, Shockley D, Charlton CG. S-adenosyl-L-methionine decreases motor activity in the rat: similarity to Parkinson’s disease-like symptoms. Behav Neural Biol 1993;59:186–93.
  10. Benson R, Crowell B, Hill B, et al. The effects of L-dopa on the activity of methionine adenosyltransferase: relevance to L-dopa therapy and tolerance. Neurochem Res 1993;18:325–30.
  11. Cheng H, Gomes-Trolin C, Aquilonius SM, et al. Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson’s disease. Exp Neurol 1997;145:580–5.
  12. Charlton CG, Crowell B Jr. Parkinson’s disease-like effects of S-adenosyl-L-methionine: effects of L-dopa. Pharmacol Biochem Behav 1992;43:423–31.
  13. Uden S, Bilton D, Nathan L, et al. Antioxidant therapy for recurrent pancreatitis: placebo-controlled trial. Aliment Pharmacol Ther 1990;4:357–71.
  14. Shaw GM, Velie EM, Schaffer DM. Is dietary intake of methionine associated with a reduction in risk for neural tube defect-associated pregnancies? Teratology 1997;56:295–9.
  15. Toborek M, Hennig B. Is methionine an atherogenic amino acid? J Optimal Nutr 1994;3:80–3.
  16. McAuley DF, Hanratty CG, McGurk C, et al. Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation. J Toxicol Clin Toxicol 1999;37:435–40.
  17. Leach FN, Braganza JM. Methionine is important in treatment of chronic pancreatitis. Br Med J 1998;316:474 [letter].